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Abstract
Observational longitudinal studies are a common means to study treatment effi-
cacy and safety in chronic mental illness. In many such studies, treatment changes
may be initiated by either the patient or by their clinician and can thus vary widely
across patients in their timing, number, and type. Indeed, in the observational longi-
tudinal pathway of the STEP-BD study of bipolar depression, one of the motivations
for this work, no two patients have the same treatment history even after coarsening
clinic visits to a weekly time-scale. Estimation of an optimal treatment regime using
such data is challenging as one cannot naively pool together patients with the same
treatment history, as is required by methods based on inverse probability weighting,
nor is it possible to apply backwards induction over the decision points, as is done in
Q-learning and its variants. Thus, additional structure is needed to effectively pool
information across patients and within a patient over time. Current scientific theory
for many chronic mental illnesses maintains that a patient’s disease status can be
conceptualized as transitioning among a small number of discrete states. We use this
theory to inform the construction of a partially observable Markov decision process
model of patient health trajectories wherein observed health outcomes are dictated
by a patient’s latent health state. Using this model, we derive and evaluate estima-
tors of an optimal treatment regime under two common paradigms for quantifying
long-term patient health. The finite sample performance of the proposed estimator
is demonstrated through a series of simulation experiments and application to the
observational pathway of the STEP-BD study. We find that the proposed method
provides high-quality estimates of an optimal treatment strategy in settings where
existing approaches cannot be applied without ad hoc modifications.
Keywords: dynamic treatment regime; infinite-horizon; Markov decision processes
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1 Introduction
A treatment regime is a set of decision rules that determines a personalized treatment
plan based on evolving treatment and covariate history (Murphy, 2003; Chakraborty and
Murphy, 2014; Tsiatis et al., 2019). An optimal treatment regime maximizes the mean
of some cumulative measure of patient health across a target population. Thus, there is
keen interest in the development of statistical methodology for the estimation of optimal
treatment regimes both to inform clinical practice and to generate new hypotheses about
heterogeneous treatment effects (Athey and Imbens, 2016; Wager and Athey, 2018). Sem-
inal methods for estimating optimal treatment regimes from observational or randomized
studies included g-estimation (Robins, Robins; Murphy, 2003; Robins, 2004), Q-learning
and its variants (Murphy, 2005; Moodie et al., 2007; Henderson et al., 2010; Schulte et al.,
2014; Moodie et al., 2014; Song et al., 2015; Taylor et al., 2015; Zhang et al., 2018; Ertefaie,
2019), and inverse probability weighting (Robins, 1999; Murphy et al., 2001; van der Laan,
2006; Robins et al., 2008). More recently, there has been a surge of research on extend-
ing these methods to make them more flexible, e.g., through the use of machine learning
methods (Zhao et al., 2012; Zhang et al., 2012; Rubin and van der Laan, 2012; Moodie
et al., 2014; Zhao et al., 2009, 2015; Laber and Zhao, 2015; Luedtke and van der Laan,
2016; Xu et al., 2016; Wager and Athey, 2018; Tao et al., 2018; Jiang et al., 2019; Luck-
ett et al., 2019; Liu et al., 2019), or to allow them to work with high-dimensional feature
spaces or other complex data structures (Lu et al., 2013; McKeague and Qian, 2014; Tian
et al., 2014; Song et al., 2015; Ciarleglio et al., 2015, 2016; Laber and Staicu, 2017; Shi
et al., 2018; Ertefaie, 2019; Wallace et al., 2019; Shi et al., 2019). While the literature on
treatment regimes is rich and growing rapidly, the types of data to which these methods
apply is restrictive. Existing methods for finite-time-horizon decision problems require that
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one be able to align patient treatment decisions in time and that the conditional average
treatment effect at each decision point be estimated using either regression or weighting
methods. For indefinite-time-horizon problems, existing methods for estimating optimal
treatment regimes require that the data-generating distribution have sufficient structure
to allow pooling of data over time points and extrapolation to future decisions, e.g., the
data-generating model might be assumed to be a contextual bandit or a homogeneous
Markov decision process (MDP, Tewari and Murphy, 2017; Ertefaie, 2019; Luckett et al.,
2019; Liao et al., 2019). Thus, existing methods do not apply to observational data with
frequent and irregularly spaced treatment changes as patients cannot be properly aligned
nor can the data be reasonably assumed to be Markov. For an example of such data,
see Figure 1, which displays patient treatment histories for a subset of patients from the
STEP-BD observational care pathway.
We propose a method for estimating an optimal treatment regime in the indefinite-time-
horizon setting when data are irregularly spaced, contain multiple treatment changes, and
cannot be assumed to be Markov. Motivated by the underlying clinical science of bipolar
depression and other episodic chronic illnesses, we assume that a patient’s health status is
dictated by a latent (unobserved) state and a subset of their observable data; we assume
that conditional on current patient information and this latent state, the evolution of a
patient’s health status is Markov. Treatment is allowed to affect the transition dynamics
of the latent process as well as patient observables. We show that under this model the
optimal treatment regime is determined by the so-called information state, which comprises
the conditional distribution of the latent state and current patient measurements. We sub-
sequently derive estimators of the optimal treatment regime and establish their asymptotic
operating characteristics.
The proposed model is an example of a partially observable MDP (POMDP, Monahan,
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1982). POMDPs have been studied extensively in the computer science literature with ap-
plications in robotics, scheduling, videogames, and wildlife management (see, for example,
Kaelbling et al., 1998; Cassandra, 1998; J Pineau, 2003; Hansen, 1998; Ji et al., 2007; Sutton
et al., 2018). The primary contributions of this work include: a theory-driven construction
of the latent-process model, the application of POMDPs to episodic chronic mental illness,
and the development of valid statistical inference for clinically relevant estimands in this
context. The proposed methodology is extensible and could be ported for estimation and
inference with optimal treatment regimes in other contexts that have complex treatment
and observation patterns, e.g., mobile-health.
The remainder of this manuscript is organized as follows. In Section 2, we formally
introduce the latent state model and show that the information state is, in some sense,
minimally sufficient for the optimal treatment regime. In Section 3, we review estimation of
optimal treatment regimes under an MDP model. In Section 4, we derive estimators of the
optimal treatment regime based on a data-driven transformation of the observed process
which makes it approximately Markov and thus amenable to the methods reviewed in
Section 3. In Section 5, we derive the asymptotic distributions of the proposed estimators.
In Section 6, we study the finite sample performance of the proposed methods through
an extensive suite of simulation experiments. In Section 7, we provide an illustrative
application using the observational care pathway of the STEP-BD bipolar disorder study.
We provide a concluding discussion in Section 8.
2 Setup and preliminary results
We use uppercase letters, e.g., X, T , and A, to denote random variables and lower case
letters, e.g., x, t, and a, to denote instances of these random variables. The symbol ‘,’ is
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used to distinguish definitions from equalities. The observed data are assumed to comprise
n i.i.d. copies, one per patient, of the trajectory
{(
T j, Aj,Xj
)}J
j=1
, where J ∈ Z+ is
the number of clinic visits, 0 = T 1 < T 2 < · · · < T J ≤ 1 encode clinic visit times;
Aj = A(T j) ∈ A = {1, . . . , L} denotes the assigned treatment during period [T j, T j+1);
and Xj = X(T j) ∈ Rp denotes a patient’s health status at time T j, j = 1, . . . , J . Thus, both
the number and timing of clinic visits are treated as random quantities. Let H1 ,
{
T 1,X1
}
and Hj ,
{
Hj−1, Aj−1, T j,Xj
}
so that Hj contains the patient history available to the
decision maker at clinic visit T j before treatment Aj is assigned.
Let D denote the space of probability distributions over A (i.e., the L-dimensional
probability simplex). We encode elements d ∈ D as vectors in [0, 1]L so that da represents
the probability of selecting action a ∈ A under d. A treatment regime in this setting is
a sequence of decision rules pi = {pij}j≥1, one per clinic visit, with pij : supp Hj → D, so
that under pi a patient presenting with Hj = hj at clinic visit j would receive treatment
recommendation a with probability pija(h
j). Whereas the observed data comprise finite
patient trajectories, we are interested in estimating treatment regimes that can be applied
indefinitely; that is, they can be used to provide treatment recommendations for as long
as the patient is receiving care. To this end, we consider treatment regimes composed of
decision rules pij = ρ◦f j, where f = {f j}j≥1 are summary functions f j : supp Hj → S ⊆ Rq,
so that Sj = f j(Hj) is a summary of patient history Hj, and ρ : S → D is a stationary
decision rule acting on patient summaries. Write pi = ρ ◦ f to denote the composed regime
pij = ρ ◦ f j for all j ≥ 1. We will show below that restricting attention to composed
regimes of this type incurs no loss of generality. Furthermore, because ρ remains fixed in
this representation, the regime can be vetted for clinical validity by domain experts when
the summary functions provide ‘qualitatively similar’ summaries of the patient history (we
show that the natural choice of summary function in our domain produces such summaries).
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The immediate utility associated with history Hj and treatment Aj is U j = U(Sj, Aj) ∈
R and is thus assumed to depend on the history only through its summary. Note that
the summary function can always be chosen to ensure that this holds. Let Epi denote
expectation with respect to the probability distribution induced by following the treatment
recommendations given by pi (for a formal development using potential outcomes, see the
Supplemental Material; see also Tsiatis et al. (2019)). We consider the following two
measures of cumulative utility:
(i) discounted mean utility
Vdis(pi) , Epi
∑
j≥1
(
γj−1U j
)
,
where γ ∈ [0, 1) is a discount factor, and
(ii) average utility
Vave(pi) , lim
N→∞
Epi
(
1
N
N∑
j=1
U j
)
.
These two cumulative measures are used almost exclusively in indefinite decision problems
(Powell, 2007; Busoniu et al., 2017; Sutton et al., 2018), though the proposed methods could
be extended to hyberbolic discounting or other notions of cumulative utility (Fedus et al.,
2019). We write V (pi) without a subscript to generically denote either of these cumulative
utility measures. We say that piopt is optimal with respect to V if V (piopt) ≥ V (pi) for all
pi. Without imposing additional structure on the data-generating model, it is not possible
in general to identify piopt from data collected over a finite time-horizon even as n→∞.
We assume that there exists a (latent) Markov process M(t) ∈ {1, . . . , K} for all t that
represents a critical component of a patient’s health status, e.g., in bipolar depression this
might represent whether the patient is in a depressive, manic, hypomanic, mixed, or stable
episode. Furthermore, we assume that:
(A1) Xj+1 ⊥ (Hj−1, Aj−1)∣∣Xj, Aj,M(T j),
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so that the process is conditionally Markov given the latent state, i.e., given a summary
of a patient’s (observable) history, Xj, their latent health state, and current treatment,
the future is independent of the past. The following result shows that the conditional
distribution of the latent state given the available history is sufficient for the optimal
regime.
Lemma 2.1. Assume (A1) and for each j ≥ 1 let Bj ∈ [0, 1]K be such that Bj` =
P
{
M(T j) = `
∣∣Hj} for ` = 1, . . . , K. Define f j(Hj) , (Bj,Xj) and write Sj = f j(Hj)
with S = supp Sj. If U jdepends on (Hj, Aj) only through (Sj, Aj)∗ then:
(i)
{(
Sj, Aj, U j
)}
j≥1 is a homogeneous MDP, and
(ii) supρ:S→D V (ρ ◦ f) = suppi V (pi).
Remark 2.1. The summary Sj is minimally sufficient in that there exists generative models
in which any further reduction of the history, e.g., learning a strategy that depends on
Rj = gj(Sj) where ||Cov(Sj|Rj)|| > 0 w.p.1., leads to degradation in the value of the
learned strategy. See the Supplemental Material for a precise statement and example.
Lemma 2.1 establishes that we can characterize the optimal regime in terms of the MDP{
(Sj, Aj, U j)
}
j≥1, which admits a stationary optimal regime, pi
opt = arg maxρ:S→D V (ρ◦ f).
Thus, the structure provided by the MDP reduces the problem of estimating an optimal
treatment regime from a search over the space of countable sequences of functions, each
acting on a different domain, to a search for a single function mapping S into D (this
is why, hereafter, we reference regimes using the unbolded pi; see ?Sutton et al., 2018, for
∗ As noted previously, the utility is typically a function of observables, and thus Xj can always be
defined so as to include U j . However, this assumption also allows for utility to be the posterior of some
latent patient characteristic given the history and treatment.
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additional discussion of the structure induced by MDPs). Were trajectories from this MDP
observed, an estimated optimal regime could be obtained by solving estimating equations
based on the Bellman optimality conditions; we review these estimating equations in the
next section. As the states Sj, j ≥ 1 are not fully observed, we first construct estimators{
Ŝ
j
n
}J
j=1
of
{
Sj
}J
j=1
, and then plug them into the MDP estimating equations. Asymptotic
results for estimators of this type are provided in Section 5.
3 Optimal treatment regimes in an MDP
Recall that our approach is to transform the observed data so that it mimics data collected
under the homogeneous MDP of Lemma 2.1. To illustrate how this transformed data will
be used, we briefly review two established methods for estimating an optimal treatment
regime in an MDP. Our developments closely follow Murphy et al. (2016), Ertefaie (2019),
and Luckett et al. (2019). For a more general treatment of MDPs see Sutton et al. (2018)
and Wiering and Van Otterlo (2012). For the purpose of describing these methods, assume
that the observed data are
{
(Sji , A
j
i , U
j
i ), j = 1, . . . , Ji
}n
i=1
, which consist of n independent
trajectories from a homogeneous MDP. We assume that the states Sj ∈ S ⊂ Rq, there are a
finite number of treatment options coded so that Aj ∈ {1, . . . , L}, and the utilities U j ∈ R
are coded so that higher values are better. We present estimating equations for the optimal
treatment regime with both the discounted and average utility criteria. Technical conditions
needed for unbiasedness of these estimating equations and asymptotic normality of the
resultant estimators applied to the transformed data,
{
(Ŝ
j
n,i, A
j
i , U
j
i ), j = 1, . . . , Ji
}n
i=1
, are
provided in Section 5.
For any regime pi and state s, define the discounted state-value function νdis(pi, s) =
Epi
(∑
j≥0 γ
jU t+j
∣∣St = s), which does not depend on t because the MDP is assumed to be
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homogeneous (Puterman, 2014). For any distribution R on S, termed a reference distri-
bution, define V Rdis(pi) =
∫
νdis(pi, s)dR(s) then Vdis(pi) = V
R0
dis (pi), where R0 is the initial
state distribution. Because R0 is unknown, one might take the empirical distribution of S
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or some other reference distribution constructed from historical data (see Luckett et al.,
2019). Define piopt,R = arg maxpi∈Π V Rdis(pi), where Π denotes a class of regimes of interest.
In the discounted utility case it can be shown (e.g., Luckett et al., 2019) that the state-value
function satisfies the following recursion
0 = E
[
piAj(S
j)
P (Aj
∣∣Sj) {U j + γνdis(pi,Sj+1)− νdis(pi,Sj)}φ(Sj)
]
, (1)
for all j and any φ : S → Rd, where the ratio piAj(Sj)/P (Aj|Sj) is an importance sampling
weight. Let V = {νdis(Sj;α) : α ∈ Ω ⊆ Rd} be a parametric class of continuously differ-
entiable maps from S into Rd; we have overloaded the notation νdis to reflect that each
regime pi will be associated with a corresponding parameter vector α. For each pi ∈ Π,
define α∗(pi) to be the solution to (1) at pi. An estimator α̂n(pi) of α∗(pi) is given by the
solution of the sample analogue of (1) with φ(Sj) = ∇αν(Sj;α), i.e., the solution to
0 = Pn
J−1∑
j=1
[
piAj(S
j)
P (Aj
∣∣Sj) {U j + γνdis(Sj+1;α)− νdis(Sj;α)}∇ανdis(Sj;α)
]
, (2)
where Pn denotes the empirical measure. The estimated optimal regime is obtained by
maximizing the estimated integrated state-value function over the class of regimes so that
piRdis,n = argmaxpi∈Π
∫
νdis {s; α̂n(pi)} dR(s).
Properties of this estimator—applied to data from a homogeneous MDP—are provided in
Luckett et al. (2019). We assumed for simplicity that P (Aj|Sj) was known, e.g., if the
data were from a randomized clinical trial; if these propensities were unknown, they could
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be estimated from the observed data, e.g., using a multinomial logistic regression (see also
Jiang and Li, 2015; Thomas and Brunskill, 2016; Hanna et al., 2018, for related ideas and
discussion).
An estimating equation for the average utility setting is derived using a similar strategy
to the discounted case. For each pi define the differential value
δ(pi, s) , lim
N→∞
Epi
[
N∑
j=1
{
U j − Vave(pi)
} ∣∣∣∣S1 = s
]
,
which is well-defined under the regularity conditions provided in Section 5. Then it can be
shown (e.g., Puterman, 2014; Murphy et al., 2016; Liao et al., 2019) that Vave(pi) satisfies
the recursion
0 = E
[
piAj(S
j)
P (Aj|Sj)
{
U j − Vave(pi) + δ(pi,Sj+1)− δ(pi,Sj)
}
ψ(Sj)
]
, (3)
for all j and any ψ : S → Re. LetW = {δ(s; β) : β ∈ B ⊆ Re−1} be a class of continuously
differentiable maps from S into Re. An estimator V̂ave,n(pi) of Vave(pi) is obtained by jointly
solving the sample analog of (3) for β and Vave(pi) with ψ(s) = {1,∇βδ(s; β)ᵀ}ᵀ so that
V̂ave,n(pi), β̂n(pi) solve
0 = Pn
J−1∑
j=1
[
piAj(S
j)
P (Aj|Sj)
{
U j − Vave(pi) + δ(pi,Sj+1; β)− δ(pi,Sj; β)
}( 1
∇βδ(Sj; β)
)]
. (4)
The estimated optimal regime is thus given by piave,n = arg maxpi∈Π V̂ave,n(pi).
Remark 3.1. The remainder of this manuscript is focused on constructing the transformed
process and examining the theoretical and empirical properties of the foregoing two estima-
tors when applied to the transformed data. However, these are but two of many possible
methods for estimating an optimal regime with MDPs; these were chosen because they have
been used previously in clinical applications and, furthermore, are simple, extensible, and
10
amenable to statistical inference (for alternative approaches see Szepesva´ri, 2010; Powell,
2007; Sutton et al., 2018, and references therein).
4 Estimation of sufficient summary functions
Recall that the sufficient summary functions are given by f j(Hj) =
(
Bj,Xj
)
for j ≥ 1. As
Xj is observed, constructing an estimator of f j is tantamount to constructing an estimator
of Bj, the conditional distribution of the latent state given history Hj. We develop an
estimator of Bj under the assumption that the observables, Xj, evolve under a latent-
state-dependent autoregressive process. This choice is motivated by the clinical theory
underpinning bipolar disorder as well as its robustness and utility in modeling chronic
illness (for additional discussion on time series and mechanistic models for bipolar disorder,
see Daugherty et al., 2009; Bonsall et al., 2011; Moore et al., 2012, 2014; Bonsall et al.,
2015; Holmes et al., 2016, and references therein).
We assume that the latent state M(t) follows a homoegenous Markov process the dy-
namics of which are described by the transition rate matrix Q(a) , {qk,`(a)}k,`=1,...,K ∈
RK×K for each a ∈ {1, . . . , L}, where
qk,k(a) , − lim
t→0+
t−1P{M(T j+1) 6= k|T j+1 − T j = t,M(T j) = k,Aj = a},
qk,`(a) , lim
t→0+
t−1P{M(T j+1) = `|T j+1 − T j = t,M(T j) = k,Aj = a}, k 6= `,
from which it can be seen that qk,k(a) = −
∑
` 6=k qk,`(a) for k = 1, . . . , K (see Liu et al.,
2015). The transition rate matrix, also known as the infinitesimal generator (e.g., Pyke,
1961a,b; Albert, 1962), induces the following transition probabilities
P{M(t′) = `|M(t) = k,A = a} = [exp{(t′ − t) ·Q(a)}]k,`,
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for t′ > t and k, ` = 1, . . . , K. To identify the transition rate matrix, we need to link
the observed data to the latent state process. This link is established by the following
assumption:
(A2) Xj ⊥M(T 1), A1,X1, . . . ,M(T j−1), Aj−1∣∣M(T j),Xj−1 for all j ≥ 2.
Furthermore, we posit parametric models for the dynamics of the observed data and assume
that these models have densities of the following form: the density of X1 given M(T 1) = m1
is pX1|M(T 1)(x
1|m1;θ), which is indexed by θ ∈ Θ, and the density of Xj given M(T j) = mj
and Xj−1 = xj−1 is pXj |M(T j),Xj−1(x
j|mj,xj−1;γ), which is indexed by γ ∈ Γ. For example,
a Gaussian autoregressive model with linear mean models takes the form:
pX1|M(T 1)(x
1|m1;θ) ∝ |Σm1|−1/2 exp
{
−1
2
(x1 − µm1)ᵀΣ−1m1(x1 − µm1)
}
,
where θ = {(µm,Σm)}m=1,...,K are unknown parameters, and
pXj |M(T j),Xj−1(x
j|mj,xj−1;γ) ∝
|Σmj |−1/2 exp
{
−1
2
(xj −Ψmjxj−1)ᵀΣ−1mj(xj −Ψmjxj−1)
}
,
where γ = {(Ψm,Σm)}m=1,...,K . We use this model in our simulation experiments and
application to the data from the STEP-BD trial.
Let % = (θ,γ) ∈ Θ × Γ denote the unknown parameters indexing the latent Markov
process. It can be seen that Bj is determined by Hj and %, i.e., Bj = bj(Hj,%) where
bj is a deterministic map from dom Hj × (Θ × Γ) into D, the L-dimensional probability
simplex. We construct an estimator %̂n via maximum likelihood implemented using the
forward-backward algorithm (for a review see Rabiner, 1989) and subsequently compute the
plug-in estimator B̂
j
n = b
j(Hj, %̂n) so that Ŝ
j
n = (B̂
j
n,X
j). The preceding estimator is used
to convert i.i.d. trajectories of the form
{(
T ji , A
j
i ,X
j
i
)}Ji
j=1
for i = 1, . . . , n into trajectories
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drawn from an (approximate) homogeneous MDP
{
(Ŝ
j
n,i, A
j
i , U
j
i )
}Ji
j=1
for i = 1, . . . , n,
which can then be used with the estimators of an optimal regime described in the previous
section.
5 Theoretical properties
We establish consistency and asymptotic normality for the estimated optimal regime con-
structed by solving estimating equations as described in the preceding section. For sim-
plicity, in Sections 5.2 and 5.3 we assume that the class of regimes Π is finite. However,
this assumption is not limiting as given an arbitrary η > 0 one can approximate any sep-
arable collection of regimes, Π˜, by a finite mesh, Π, so that suppi∈Π V (pi) is within η of
suppi∈Π˜ V (pi). We illustrate this approach in Section 5.4 in the derivation of confidence sets
for the value of the optimal regime within a parametric class of regimes (see Zhang et al.,
2018, for additional discussion).
5.1 Consistency of the estimated state probabilities
Consistency of the estimated latent state distribution is central to characterizing the large
sample behavior of estimators of the optimal treatment regime constructed by solving
the MDP estimating equations of Section 3. Consistency follows from existing results on
maximum likelihood for latent Markov models and the continuous mapping theorem. We
make the following assumptions.
(B1) Both the time process (T j : j ∈ N) and the number of time points J are independent
of the latent process {M(t) : t ≥ 0}.
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(B2) The true parameter vector %∗ is an interior point of Θ×Γ, where Θ×Γ is a compact
subset of Rdim %.
(B3) For all m1 ∈ {1, . . . , K}, P{M(T 1) = m1} > 0.
(B4) There exist measures υ1, υ2 on X which are bounded away from zero with
pX1|M(T 1)(·|m1) ≥ υ1(·) for all m1 ∈ {1, . . . , K},
pXj |M(T j),Xj−1(·|mj,xj−1) ≥ υ2(·) for all mj ∈ {1, . . . , K},xj ∈ X , j > 1,
where X = dom Xj , j ≥ 1.
(B5) For each % ∈ Θ×Γ, the transition kernel indexed by % is stationary, Harris recurrent,
and aperiodic (see Athreya and Lahiri, 2006; Meyn and Tweedie, 2012, for additional
discussion of this assumption and its implications).
(B6) The transition kernel is continuous in % in an open neighborhood of %∗.
(B7) The latent Markov process is identifiable up to label switching of the latent states
(see Allman et al., 2009; Gassiat et al., 2013, for discussions of label-switching).
(B8) The log likelihood is twice continuously differentiable in % and the Fisher information
I(%) is positive definite in an open neighborhood of %∗ (see Bickel et al., 1998; Jensen
and Petersen, 1999; Douc et al., 2004, for equivalent assumptions).
(B9) For any %1,%2 ∈ Θ × Γ, ‖bj(hj,%1) − bj(hj,%2)‖ ≤ gj(hj)‖%1 − %2‖, for some
integrable function gj : dom Hj → R, j ≥ 1.
The preceding assumptions are relatively mild and standard in hidden Markov models.
Assumption (B1) ensures that the distribution of the visit times factors out of the likelihood
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for %, i.e., the time process and latent process do not share parameters. Assumptions (B2)-
(B8) ensure that the model is well-defined and that the maximum likelihood estimators are
regular (Leroux, 1992; Bickel et al., 1998; Jensen and Petersen, 1999; Le Gland and Mevel,
2000; Douc and Matias, 2001; Douc et al., 2004). Consistency and asymptotic normality of
the maximum likelihood estimators in general autoregressive hidden Markov models have
been established under the preceding conditions (Douc et al., 2004). Moreover, we will
show that Assumption (B9) holds for the Gaussian autoregressive hidden Markov model
in the Supplementary Material, which ensures the class is Donsker and thus consistency of
the estimated state probabilities follows immediately.
Lemma 5.1. Assume (A1) - (A2), (B1) - (B8), as n→∞:
√
n(%̂n − %∗) N{0, I(%∗)−1},
√
n{bj(hj; %̂n)− bj(hj;%∗)} N{0,∇%bj(hj;%∗)I(%∗)−1∇%bj(hj;%∗)ᵀ},
for each hj ∈ dom Hj. Furthermore, if (B9) holds, then for each fixed j = 1, . . . , J , as
n→∞,
sup
hj∈domHj
∣∣bj(hj, %̂n)− bj(hj, %∗)∣∣ p→ 0.
5.2 Asymptotic properties in the discounted utility setting
We consider linear working models for the state-value function ν(s;α) = φ(s)ᵀα, where φ
is a finite-dimensional set of basis functions; these basis functions might comprise custom
features informed by domain expertise as well as nonlinear expansions such as b-splines or
radial basis functions. Using this functional form, the population-level estimating equation
for the state value-function, i.e., (1) from Section 3, is given by
Λdis(pi,α) , E
J−1∑
j=1
[
piAj(S
j)
P (Aj
∣∣Sj) {U j + γφ(Sj+1)ᵀα− φ(Sj)ᵀα}φ(Sj)
]
;
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let α∗(pi) denote the solution to Λdis(pi,α) = 0. The sample analog using the estimated
states is thus
Λ̂dis,n(pi,α) , Pn
J−1∑
j=1
 piAj
(
Ŝ
j
n
)
P
(
Aj
∣∣Ŝjn)
{
Û jn + γφ
(
Ŝ
j+1
n
)ᵀ
α− φ
(
Ŝ
j
n
)ᵀ
α
}
φ
(
Ŝ
j
n
) ,
where Û jn = U(Ŝ
j
n, A
j); let α̂n(pi) denote a solution to Λ̂dis,n(pi,α) = 0. For linear estima-
tors, such a root always exists, however, below we require the weaker condition that α̂n(pi)
is an approximate root. Let || · ||F denote the Frobenius norm. We make the following
assumptions.
(C1) For each pi ∈ Π, α∗(pi) solves Λdis(pi,α) = 0, where α∗(pi) is an interior point of Ω
and Ω is a compact subset of Rdim α.
(C2) For each pi ∈ Π, there exists a sequence of α̂n(pi) ∈ Ω such that Λ̂dis,n{pi, α̂n(pi)} =
op(n
−1/2).
(C3) Define V Rdis(pi) ,
∫
φ(s)ᵀα∗(pi)dR(s), which attains its supremum at pi∗dis ∈ Π.
(C4) There exists a sequence of pidis,n ∈ Π such that V̂ Rdis,n(pidis,n) ≥ suppi∈Π V̂ Rdis,n(pi)−op(1).
(C5) There exists a constant c > 0, such that
ωᵀE
[
piAj(S
j)
P (Aj|Sj)φ(S
j)
{
φ(Sj − γφ(Sj+1)
}ᵀ]
ω ≥ c‖ω‖22,
for all j ≥ 1 and ω 6= 0.
(C6) φ : S → Rd is uniformly continuous, where S = dom Sj , j = 1, . . . , J , is compact,
and J is finite almost surely. Furthermore, E||Sj||2 < κ for some κ > 0 and all j ≥ 1.
(C7) For each a ∈ A, s ∈ S, j ≥ 1, P (Aj = a|Sj = s) ≥ , for some  > 0.
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(C8) For each j = 1, . . . , J , pi ∈ Π, define
Gjdis
(
pi,hj, aj;%
)
,
piaj
{
bj(hj;%)
}
P
{
aj|bj(hj;%)}U {bj (hj;%) , aj}φ{bj (hj;%)} .
There exists a linear operator Wjdis(pi,h
j, aj;%) such that E||Wjdis(pi,Hj, Aj;%)||F <
∞ and, for all hj ∈ dom Hj and aj ∈ A, the following expansion holds
Gjdis
(
pi,hj, aj; %̂n
)−Gjdis (pi,hj, aj;%∗) = Wjdis(pi,hj, aj;%∗)(%̂n − %∗) + op(n−1/2).
These conditions are standard for Z-estimators (van der Vaart and Wellner, 1996; Kosorok,
2008). Conditions (C1), (C2), (C6), and (C7) are used to establish the consistency of
α̂n(pi), while the addition of (C5) and (C8) are used to establish asymptotic normality.
A sufficient condition for (C8) is that Gjdis(pi,h
j, aj;%) is almost everywhere differentiable
in % in which case Wjdis(pi,h
j, aj;%) can be chosen to be the gradient operator. We use
(C3) and (C4) to show V̂dis,n(pidis,n)
p→ Vdis(pi∗dis), which is a weaker but more general result
than pidis,n
p→ pi∗dis. Convergence of pidis,n generally requires that pi∗dis is a unique and well-
separated maximizer of Vdis(pi), which need not hold for some commonly used classes of
regimes (see Zhang et al., 2018).
Theorem 5.1. Assume (A1) - (A2), (C1) - (C7), and that Π is finite. Then as n→∞:
1. for any fixed regime pi, α̂n(pi)
p→ α∗(pi);
2. V̂dis,n(pidis,n)
p→ Vdis(pi∗dis).
To define the limiting distribution of the estimated optimal value we make use of the
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following quantities:
C1(pi) ,E
[J−1∑
j=1
piAj(S
j)
P (Aj|Sj)φ(S
j)
{
φ(Sj)− γφ(Sj+1)
}ᵀ]
,
Ĉ1,n(pi) ,Pn
[J−1∑
j=1
piAj(Ŝ
j
n)
P (Aj|Ŝjn)
φ(Ŝ
j
n)
{
φ(Ŝ
j
n)− γφ(Ŝ
j+1
n )
}ᵀ]
,
C2(pi, pi) ,E
[J−1∑
j=1
piAj(S
j)piAj(S
j)
P 2(Aj|Sj)
{
U j + γφ(Sj+1)ᵀα∗(pi)− φ{Sj}ᵀα∗(pi)
}
{
U j + γφ(Sj+1)ᵀα∗(pi)− φ(Sj)ᵀα∗(pi)
}
φ(Sj)φ(Sj)ᵀ
]
,
Ĉ2,n(pi, pi) ,Pn
[J−1∑
j=1
piAj(Ŝ
j
n)piAj(Ŝ
j
n)
P 2(Aj|Ŝjn)
{
Û jn + γφ(Ŝ
j+1
n )
ᵀα̂n(pi)− φ(Ŝjn)ᵀα̂n(pi)
}
{
Û jn + γφ
(
Ŝ
j+1
n
)ᵀ
α̂n(pi)− φ(Ŝjn)ᵀα̂n(pi)
}
φ(Ŝ
j
n)φ(Ŝ
j
n)
ᵀ
]
,
C3(pi) ,E
[J−1∑
j=1
Wjdis(pi,H
j, Aj;%∗)
]
,
Ĉ3,n(pi) ,Pn
[J−1∑
j=1
Wjdis(pi,H
j, Aj; %̂n)
]
.
Theorem 5.2. Assume (A1) - (A2), (C1) - (C8), and that Π is finite. The following
results hold as n→∞ :
1.
√
n{V̂ Rdis,n(pi)−V Rdis(pi)} B(pi), where B(pi) is a mean zero Gaussian process indexed
by pi ∈ Π with covariance
E{B(pi)B(pi)} =
[∫
φ(s)dR(s)
]ᵀ
C−11 (pi)[C2(pi, pi)+C3(pi)I
−1(%∗)Cᵀ3 (pi)]C
−ᵀ
1 (pi)
[∫
φ(s)dR(s)
]
;
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2.
√
nσ̂
−1/2
dis,n (pi)
{
V̂ Rdis,n(pi)− V Rdis(pi)
}
 N (0, 1), where
σ̂
−1/2
dis,n (pi) =
[
Pn{φ(s)}ᵀĈ−11,n(pi)[Ĉ2,n(pi, pi)+Ĉ3,n(pi)̂I
−1
n (%̂n)Ĉ
ᵀ
3,n(pi)]Ĉ
−ᵀ
1,n(pi)Pn{φ(s)}
]1/2
.
5.3 Asymptotic properties in the average utility setting
We derive the limiting distribution of the value function under a linear working model for
the differential value δ(s,β) = φ(s)ᵀβ, where φ is a vector of features constructed from s
as in the preceding section. Further, define ζ∗(pi) , {Vave(pi),β}, ψ1(s) , {1, φ(s)}ᵀ, and
ψ2(s, s˜) , {1, φ(s), φ(s˜)}ᵀ. The population estimating equation for the average utility, i.e.,
equation (3) in Section 3, under the posited model is
Λave (pi, ζ) , E
J−1∑
j=1
[
piAj(S
j)
P (Aj|Sj)
{
U j − ψ2(Sj,Sj+1)ᵀζ
}
ψ1(S
j)
]
;
define ζ∗(pi) as the solution to Λave (pi, ζ) = 0. The sample analog is
Λ̂ave,n (pi, ζ) , Pn
J−1∑
j=1
[
piAj(Ŝ
j
n)
P (Aj|Ŝjn)
{Û jn − ψ2(Ŝ
j
n, Ŝ
j+1
n )
ᵀζ}ψ1(Ŝjn)
]
,
where Û jn = U
(
Ŝ
j
n, A
j
)
; define ζ̂n(pi) as the solution to Λ̂ave,n (pi, ζ) = 0. As in the
discounted setting, one can always find an exact root to the sample estimating equation
under a linear model; however, the theory permits approximate roots as well.
To study the large sample properties of ζ̂n(pi) we make use of the following regularity
conditions.
(D1) There exists a measure υ on S which is bounded away from zero with
pSj |Sj−1,Aj−1(·|s, a) ≥ υ(·) for all s ∈ S, a ∈ A,
where pSj |Sj−1,Aj−1 denotes the density of S
j given Sj−1 and Aj−1.
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(D2) For all pi ∈ Π and s ∈ S,
lim sup
N→∞
Epi
(
1
N
N∑
j=1
U j|S1 = s
)
= lim inf
N→∞
Epi
(
1
N
N∑
j=1
U j|S1 = s
)
.
(D3) For all s ∈ S, limγ↑1
[
νdis(pi, s)− Vave(pi)/(1− γ)
]
= O(1).
(D4) For each pi ∈ Π, ζ∗(pi) solves Λave(pi, ζ) = 0, where ζ∗(pi) is an interior point of Z,
and Z is a compact subset of Rdim ζ.
(D5) For each pi ∈ Π, there exists a sequence of ζ̂n(pi) ∈ Z such that Λ̂ave,n{pi, ζ̂n(pi)} =
op(n
−1/2).
(D6) Vave(pi) attains its supremum over Π at pi
∗
ave.
(D7) There exists a sequence piave,n ∈ Π such that V̂ave,n(piave,n) ≥ suppi∈Π V̂ave,n(pi)− op(1).
(D8) There exists a constant c > 0, such that
wᵀE
{
piAj(S
j)
P (Aj|Sj)ψ1(S
j)ψ2(S
j,Sj+1)ᵀ
}
w ≥ c‖w‖22,
for all j > 0 and w 6= 0.
(D9) For each j = 1, . . . , J , pi ∈ Π, define
Gjave
(
pi,hj, aj;%
)
,
piaj
{
bj
(
hj;%
)}
P
{
aj|bj (hj;%)}U {bj (hj;%) , aj}ψ1 {bj (hj;%)} .
There exists a linear operator Wjave(pi,h
j, aj;%) such that, E||Wjave(pi,Hj, Aj;%∗)||F <
∞, and for all hj ∈ dom Hj and aj ∈ A,
Gjave
(
pi,hj, aj; %̂n
)−Gjave (pi,hj, aj;%∗) = Wjave(pi,hj, aj;%∗)(%̂n − %∗) + op(n−1/2).
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Assumption (D1) is a common condition in the average utility MDP setting (see Yamada,
1975; Kurano, 1986; Cavazos-Cadena, 1988; Herna´ndez-Lerma et al., 1991, for variants of
this assumption). This assumption ensures that there is a nonzero transition density from
any starting state to any other state under all feasible regimes. A consequence is that
Vave(pi) does not depend on the starting state. Assumption (D2) guarantees the existence
of Vave(pi) as the limit of the expected average potential utility for all pi ∈ Π. Assumption
(D3) requires the system dynamics be such that as γ ↑ 1, νdis(pi, s) behaves like the expected
total utility starting from s while Vave(pi)/(1− γ) behaves like the discounted total utility
averaging across initial states. The remainder of the assumptions are standard regularity
assumptions for Z-estimators.
Theorem 5.3. Assume (A1) - (A2), (C6) - (C7), (D1) - (D8), and that Π is finite. Then
as n→∞ :
1. For any fixed regime pi ∈ Π, ζ̂n(pi) p→ ζ∗(pi), as n→∞.
2. V̂ave,n(piave,n)
p→ Vave(pi∗ave) as n→∞.
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The following quantities will be used defining limiting distribution of ζ̂n(pi):
D1(pi) ,E
{
J−1∑
j=1
piAj(S
j)
P (Aj|Sj)ψ1(S
j)ψ2(S
j,Sj+1)ᵀ
}
,
D̂1,n(pi) ,Pn

J−1∑
j=1
piAj
(
Ŝ
j
n
)
P
(
Aj|Ŝjn
)ψ1 (Ŝjn)ψ2 (Ŝjn, Ŝj+1n )ᵀ
 ,
D2(pi, p˜i) ,E
[J−1∑
j=1
piAj
(
Sj
)
piAj
(
Sj
)
P 2
(
Aj|Sj)
{
U j − ψ2(Sj,Sj+1)ᵀζ∗(pi)
}
{
U j − ψ2
(
Sj,Sj+1
)ᵀ
ζ(pi)
}
ψ1(S
j)ψ1(S
j)ᵀ
]
,
D̂2,n(pi, pi) ,Pn
[J−1∑
j=1
piAj
(
Ŝ
j
n
)
piAj
(
Ŝ
j
n
)
P 2
(
Aj|Ŝjn
) {Û jn − ψ2 (Ŝjn, Ŝj+1n )ᵀ ζ̂n (pi)}{
Û jn − ψ2
(
Ŝ
j
n, Ŝ
j+1
n
)ᵀ
ζ̂n(pi)
}
ψ1
(
Ŝ
j
n
)
ψ1
(
Ŝ
j
n
)ᵀ]
,
D3(pi) ,E
[J−1∑
j=1
Wjave(pi,H
j, Aj;%∗)
]
,
D̂3,n(pi) ,Pn
[J−1∑
j=1
Wjave(pi,H
j, Aj; %̂n)
]
.
Corollary 5.1. Assume (A1) - (A2), (C6) - (C7), (D1) - (D9), and that Π is finite. Then
for each pi ∈ Π, as n→∞:
√
n{ω(pi)}−1/2{V̂ave,n(pi)− Vave(pi)} N (0, 1),
where ω(pi) is the element at entry (1, 1) of
D̂−11,n(pi)[D̂2,n(pi, pi) + D̂3,n(pi)̂I
−1
n (%̂n)D̂
ᵀ
3,n(pi)]D̂
−ᵀ
1,n(pi).
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5.4 Confidence intervals for value of an optimal treatment regime
The preceding results establish consistency and asymptotic normality jointly over any fixed
set of regimes under the estimated MDP. We now illustrate how these results can be used
to construct a confidence interval for the value of the optimal regime within a (possibly
infinite) class of regimes. We present only the discounted utility case as the approach for the
average utility is essentially the same. The strategy we follow here is in the same spirit as in
the construction projection confidence intervals, which are commonly used for non-smooth
functionals (see Berger and Boos, 1994; Robins, 2004; Laber et al., 2014). Let η ∈ (0, 1) be
arbitrary. An overview of the basic approach is as follows: (S1) specify a parametric class
of regimes; (S2) construct a (1− η)× 100% confidence region for the parameters indexing
the optimal regime; mapping each element in this region to its corresponding regime thus
defines a confidence region in the space of regimes; (S3) for each regime in the confidence
region, construct a (1 − η) × 100% confidence interval for its value using the asymptotic
normality of the estimated value for a fixed regime (derived in the previous section); and
(S4) take a union of all the intervals in the preceding step. It is easily shown that if the
region constructed in (S2) is a valid confidence region and each interval in (S3) is also
(marginally) valid then the union is a valid (1− 2η)× 100% interval for the optimal value.
For additional discussion see Tsiatis et al. (2019).
Our goal is to derive a confidence interval for the optimal value, suppi∈Π V
R
dis(pi), when
Π is a parametric class of regimes. We make the following assumptions.
(C9) The class of regimes Π = {pi(·; ξ) : ξ ∈ Ξ} is indexed by ξ, where Ξ is a compact
subset of Rdim ξ.
(C10) The map ξ 7→ V Rdis(ξ) ,
∫
φᵀ(s)α∗(ξ)dR(s) has a unique and well-separated maxi-
mum at ξ = ξ∗, which is an interior point of Ξ.
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(C11) There exists a sequence of ξ̂n ∈ Ξ such that V̂ Rdis,n(ξ̂n) ≥ supξ∈Ξ V̂ Rdis,n(ξ)− oP (1).
(C12) The map ξ 7→ ∫ φᵀ(s)α∗(ξ)dR(s) is twice continuously differentiable in a neighbor-
hood of ξ∗ and ∂
2ξ
∂ξ∂ξᵀ
∫
φᵀ(s)α∗(ξ)dR(s)
∣∣
ξ=ξ∗ is positive definite.
Corollary 5.2. Assume (A1) - (A2), (C1) - (C12). Then as n→∞:
1. the results in Theorem 5.2 hold over all pi ∈ Π;
2.
√
n(ξ̂n − ξ∗) N (0,Σξ), where Σξ = Σ−11,ξΣ2,ξΣ−11,ξ,
Σ1,ξ =
∫
∂2
∂ξ∂ξᵀ
φᵀ(s)α∗(ξ)dR(s)
∣∣
ξ=ξ∗ ,
Σ2,ξ =
∫ {
∂
∂ξ
φᵀ(s)α∗(ξ)
}{
∂
∂ξ
φᵀ(s)α∗(ξ)
}ᵀ
dR(s)
∣∣
ξ=ξ∗ .
Corollary 5.3. Assume (A1) - (A2), (C1) - (C12). Let η ∈ (0, 1) be arbitrary. Define
E1−η,n , {ξ : n(ξ̂n − ξ)ᵀΣ̂ξ,n(ξ̂n − ξ) ≤ χ2dim ξ,1−η},
where Σ̂ξ,n is the sample analog of Σξ. Let zη/2(ξ) and z1−η/2(ξ) be the (η/2) × 100 and
(1−η/2)×100 percentiles of a Gaussian distribution with mean-zero and variance σ̂2dis,n(ξ).
Then it follows that
P
[
inf
ξ∈E1−η,n
{
zη/2(ξ)√
n
+ V̂ Rdis,n(ξ)
}
≤ V Rdis(ξ∗) ≤ sup
ξ∈E1−η,n
{
z1−η/2(ξ)√
n
+ V̂ Rdis,n(ξ)
}]
≥ 1− 2η.
While projection intervals can be extremely conservative in some settings (see Laber
et al., 2014), in our simulation experiments, which are based on the STEP-BD study data,
the degree of conservatism was relatively mild. Thus, these intervals appear to be suitable
for application with data like STEP-BD.
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6 Simulation experiments
We study the finite sample performance of the proposed point and interval estimators using
a series of simulation experiments. The data-generating models we consider are designed
to mimic salient features of the STEP-BD trial. We consider a follow-up period of one
year. At each visit, j ≥ 1, we observe three patient covariates, Xj ∈ R3, and a treatment
is chosen from among three candidates Aj ∈ {1, 2, 3} so that
logit
{
P (Aj = 1|Hj)
P (Aj = 3|Hj)
}
= −0.2 + 0.1Xj1 − 0.1Xj2 + 0.1Xj3 ,
logit
{
P (Aj = 2|Hj)
P (Aj = 3|Hj)
}
= −0.2− 0.1Xj1 + 0.1Xj2 − 0.1Xj3 .
We consider five latent states intended to encode the health states: depression, mania,
mixed type, hypomania, and stable; thus, Bj is an element of the five-dimensional proba-
bility simplex. The jth interarrival time between visits follows an exponential distribution
with rate exp{e1 +0.1(Bj1 +Bj2)−0.1(Bj3 +Bj4)}, where e1 i.i.d.∼ Uniform(−3,−2) is a subject-
specific random effect. We assume that the conditional distribution of Xj given (M j,Xj−1)
follows a Gaussian autoregressive model (see Section 4 for the form of the density) that is
indexed by the following parameters:
State 1 : µ1 = (2, 2, 2)
ᵀ Ψ1 =
1
10
I3×3 Σ1 = 110I3×3 +
1
10
13×3,
State 2 : µ2 = (2, 1,−2)ᵀ Ψ2 = 110I3×3 Σ2 = 110I3×3 + 11013×3,
State 3 : µ3 = (−2, 1, 2)ᵀ Ψ3 = − 110I3×3 Σ3 = 310I3×3 − 11013×3,
State 4 : µ4 = (−2,−2,−2)ᵀ Ψ4 = − 110I3×3 Σ4 = 310I3×3 − 11013×3,
State 5 : µ5 = (0, 0, 0)
ᵀ Ψ5 = 03×3 Σ5 = I3×3,
where µk, Σk, and Ψk, k = 1, 2, . . . , 5, are state-dependent mean, covariance, and au-
toregression coefficients; 03×3 is a 3-by-3 matrix of zeros and 13×3 is a 3-by-3 matrix of
ones.
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In the first scenario, we consider the case where the evolution of latent disease status
follows a first-order Markov process, i.e., the generative model is correctly specified. We
consider the following utility function
U j = 2− |Xj+11 | − |Xj+13 |;
thus the utility is larger when X1 and X3 are close to 0. In these simulation experiments,
we might think of X1 and X3 as symptom severity measures represented as deviations
from a stable condition (coded as zero). The off-diagonals in the transition rate matrix
{qm,`(a)}m6=` are
logit qk,`(a) = e3 + 5 · I(a = 1) for (k, `) ∈ {(1, 5), (4, 5), (2, 3), (3, 2)},
logit qk,`(a) = e3 + 5 · I(a = 2) for (k, `) ∈ {(2, 5), (3, 5), (1, 4), (4, 1)},
logit qk,`(a) = e3 + 2 · I(a = 1) + 2 · I(a = 2) for (k, `) ∈ {(5, 1), (5, 2), (5, 3), (5, 4)},
logit qk,`(a) = e3 otherwise,
where e3
i.i.d∼ Uniform(−7,−6) are subject-specific random effects. The diagonals are thus
qk,k = −
∑
` 6=k qk,` for k = 1, . . . , 5. In this setup, treatment 1 will: (1) increase the
probability of transitioning to state 5 when the current state is either 1 or 4; (2) increase
the probability of transitioning between state 2 and 3; and (3) increase the probability of
transitioning out of state 5.
In the second scenario, we consider the case where the generative model is misspecified.
At visit j, the latent disease states are distributed according to a multinomial distribution
with parameters (p1, p2, p3, p4, p5) which are drawn from a Dirichlet distribution with pa-
rameter (1, 1, 1, 1, 1); thus, the latent disease state distribution is randomly drawn at each
visit. We consider the utility function of the form
U j = (Bj1 +B
j
4){2I(Aj = 1)− 1}+ (Bj2 +Bj3){2I(Aj = 2)− 1}+Bj5{2I(Aj = 3)− 1},
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which indicates: (1) treatment 1 is optimal when the current state is either 1 or 4; (2)
treatment 2 is optimal when the current state is either 2 or 3; and (3) treatment 3 is
optimal when the current state is 5. Because this utility is not directly observed, the
estimated optimal regime is constructed with the estimated utility; however, evaluations
are made and reported for the true utility.
We evaluate the mean and standard error of the value of candidate regimes under sam-
ple sizes 100 and 200. We consider both stochastic and deterministic regimes (stochastic
regimes are of interest in applications such as mHealth); when estimating stochastic regimes
we used an L2 penalty tuned to ensure that each treatment is selected with (estimated)
probability at least 0.05 across all observed states. The stochastic regimes we consider in-
clude the data-generating regime, the proposed POMDP regimes in the form of multinomial
logistic regression using both linear and quadratic basis functions, and their MDP regime
counterparts, which do not utilize latent state information. The deterministic regimes we
consider include the optimal regime, the proposed POMDP regimes with linear policies in-
dexed by linear and quadratic basis functions, and their MDP regime counterparts, which
do not use latent state information. All results are based on 500 Monte Carlo replications.
Table 1 shows the mean and standard error for the estimated values in scenario 1,
where the generative model is correctly specified. The proposed POMDP estimators out-
perform the baseline MDP estimators across all configurations of stochastic and determin-
istic regimes and average and discounted utilities. The POMDP estimators have higher
mean values and smaller standard errors than their MDP counterparts. Indeed, the values
from the estimated POMDP regimes are close to those of the true optimal deterministic
regime. In Table 2, where the POMDP model is misspecified, the estimated values from
the POMDP regimes still significantly outperform the observed and MDP regimes. This
result suggests that the linear model may be robust to moderate misspecification. The
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inclusion of quadratic terms did not greatly affect performance. Table 3 shows the cov-
erage probability and half-width of the proposed confidence interval for the optimal value
under linear regimes when the model is correctly specified. The confidence intervals attain
nominal (95%) coverage, although they are a bit conservative as expected.
Table 1: Mean (standard error) for the estimated values for stochastic and deterministic
regimes in scenario 1.
Stochastic regimes Deterministic regimes
n Vobs V
MDP
lin V
MDP
quad V
POM
lin V
POM
quad V
MDP
lin V
MDP
quad V
POM
lin V
POM
quad V
opt
Discounted utility
100 -4.602
(0.684)
-5.978
(3.517)
-5.888
(3.465)
1.015
(0.882)
1.037
(0.851)
-5.878
(3.527)
-5.886
(3.508)
1.213
(1.060)
1.158
(1.054)
1.144
(1.076)
200 -4.622
(0.527)
-5.321
(3.273)
-5.355
(3.279)
1.106
(0.584)
1.062
(0.606)
-5.390
(3.393)
-5.422
(3.359)
1.265
(0.701)
1.248
(0.703)
1.285
(0.689)
Average utility
100 -0.481
(0.076)
-0.951
(0.494)
-0.954
(0.500)
0.032
(0.169)
0.014
(0.164)
-0.892
(0.448)
-0.893
(0.445)
-0.079
(0.186)
-0.085
(0.181)
-0.063
(0.218)
200 -0.483
(0.052)
-0.881
(0.516)
-0.882
(0.518)
0.053
(0.110)
0.051
(0.116)
-0.808
(0.444)
-0.807
(0.442)
-0.066
(0.144)
-0.066
(0.135)
-0.017
(0.122)
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Table 2: Mean (standard error) for the estimated values for stochastic and deterministic
regimes in scenario 2.
Stochastic regimes Deterministic regimes
n Vobs V
MDP
lin V
MDP
quad V
POM
lin V
POM
quad V
MDP
lin V
MDP
quad V
POM
lin V
POM
quad V
opt
Discounted utility
100 -2.921
(0.168)
0.412
(0.152)
0.399
(0.154)
3.007
(0.153)
3.009
(0.156)
0.478
(0.154)
0.466
(0.157)
3.660
(0.162)
3.657
(0.164)
3.804
(0.091)
200 -2.909
(0.112)
0.420
(0.107)
0.420
(0.103)
3.026
(0.085)
3.024
(0.083)
0.482
(0.101)
0.491
(0.103)
3.671
(0.076)
3.672
(0.078)
3.807
(0.066)
Average utility
100 -0.343
(0.020)
0.021
(0.026)
0.021
(0.024)
0.262
(0.046)
0.263
(0.048)
0.033
(0.025)
0.031
(0.026)
0.368
(0.074)
0.370
(0.074)
0.418
(0.011)
200 -0.342
(0.014)
0.024
(0.019)
0.024
(0.019)
0.270
(0.036)
0.271
(0.035)
0.033
(0.020)
0.034
(0.021)
0.384
(0.057)
0.384
(0.057)
0.418
(0.008)
Table 3: Coverage probability and half width of the confidence intervals at 0.05 nominal
level for the linear POMDP regimes when the model is correctly specified.
Coverage probability Half width
Criterion n Stochastic Deterministic Stochastic Deterministic
Discounted 100 0.986 0.986 1.378 1.451
Discounted 200 0.988 0.984 0.966 1.010
Average 100 0.982 0.980 0.238 0.225
Average 200 0.978 0.990 0.175 0.185
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7 Case study
The data used in our case study are derived from the standard care pathway of the STEP-
BD clinical trial (Sachs et al., 2003). Inclusion criteria required that patients be (i) at least
18 years old and (ii) diagnosed with bipolar type I or bipolar type II disorder at screening.
Treatment decisions at each clinic visit were made based on doctor-patient preference and
thus the data are observational. Validity of the proposed methods thus requires additional
causal assumptions. As these assumptions are standard, we have relegated them to the
Supplemental Material.
Figure 1 shows the treatment histories for a sample of patients in the STEP-BD obser-
vational pathway. It can be seen that the timing, number, type, and dosage of treatment
varies widely across patients. We categorize each medication being either an (A) antide-
pressant or a (M) mood stabilizers; and we categorize the dose level for each drug as low,
medium, or high. The categorization of antidepressants and mood stabilizers as well as the
corresponding dose levels are provided in Appendix I. Table 4 enumerates the 15 potential
treatment combinations.
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Treatment ID Treatment combinations
1 low A
2 medium A
3 high A
4 low M
5 medium M
6 high M
7 low A + low M
8 low A + medium M
9 low A + high M
10 medium A + low M
11 medium A + medium M
12 medium A + high M
13 high A + low M
14 high A + medium M
15 high A + high M
Table 4: List of potential treatment combinations. A = antidepressants, M = mood stabi-
lizers.
We assume that there are five latent health states corresponding to: depression, mania,
mixed type, hypomania, and stable moods. At each stage, a patient’s estimated state
comprises the latent health state probability vector and observable patient covariates: age,
bipolar disorder type, sum of depression score (SUMD), sum of mania score (SUMM),
percent of days depressed, percent of days low interest in most activities, and percent of
days with abnormal mood elevation. SUMD and SUMM are aggregates of multiple items on
a questionnaire. In the study protocol, both SUMD and SUMM are defined to be missing
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when an answer to any of the inventory questions is missing, this results in 19% and 36%
missing entries, respectively. We used multiple imputation (Rubin, 2004) for missing items
and recalculated aggregated scores using the imputed data. Besides the inventory questions
in SUMD and SUMM, other variables used in multiple imputation include the three other
continuous patient covariates as well as patient baseline characteristics (details and code
are provided in Supplemental Material). We imputed five complete data sets, and to each
imputed data set we applied the proposed methodology to estimate the optimal treatment
regime. Parameters indexing each estimated optimal treatment regime were averaged and
used in the final estimated optimal treatment regime. The utility at each stage is defined
as 2 − SUMD − SUMM, where both SUMD and SUMM are standardized to lie between
zero and one. A higher utility implies a lower SUMD and SUMM, which corresponds to
a more desirable clinical outcome. Wu et al. (2015) used SUMD as the clinical outcome
in estimating the optimal treatment regime in the randomized arm of STEP-BD, where
there were only two decision stages. However, an effective long-term treatment regime for
bipolar disorder should alleviate depression symptoms without inducing mania episodes,
which is why we opted for a composite outcome.
Table 5 shows the mean and standard error of the estimated mood state probabilities
using the proposed latent Markov model. The results are promising in that they largely
agree with the reported clinical status on the clinical monitoring form.† The model had
some difficulty delineating between mania and hypomania; however, this is not surprising
as (clinically) these abnormal states differ only in severity.
†Such assessments were collected in the trial and thus can serve as a kind of gold standard. However,
these are not collected as a matter of course in standard clinical care which is why they were not used in
the modeling. In cases where such assessments are made at each visit, they can be folded into the
observed state as noisy surrogate for the true latent state at the visit time.
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Table 6 shows the value under the observed regime and under the estimated regime for
average utility and discounted utility (γ = 0.95). In both cases, the lower bound of the
95% confidence interval for the value of the estimated regime is higher than the observed
regime.
Figure 2 shows the estimated optimal treatment regime obtained by maximizing the
average utility, which is projected onto a decision tree for ease of interpretation. The pre-
dicted optimal treatment is either mood stabilizers or a combination of mood stabilizers
and antidepressants, i.e., it never recommends antidepressants alone. Such recommenda-
tions are anticipated by the clinical belief that prescribing antidepressants alone for bipolar
disorder patients may increase the risk of inducing a manic episode (Patel et al., 2015).
The estimated optimal regime also prescribes antidepressants only as a supplement for the
mood stabilizer either when there is some evidence of depression (SUMD is large or the
probability of depression is large) or there is little evidence of mania (SUMM is small or the
probability of mania is small). The estimated optimal treatment regime for the discounted
utility (γ = 0.95) is included in the Appendix and is qualitatively similar.
Clinical status P̂ (Depress) P̂ (Mania) P̂ (Mixed) P̂ (Hypomania) P̂ (Stable)
Depression 0.85 <0.01 0.14 <0.01 0.05
Mania <0.01 0.55 0.05 0.47 <0.01
Mixed 0.13 0.09 0.84 0.08 <0.01
Hypomania <0.01 0.34 0.09 0.44 0.02
Stable 0.02 <0.01 <0.01 <0.01 0.92
Table 5: Mean estimated mood state probabilities within each of the five clinical status
categories. The standard errors range from 0.0001 to 0.01.
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Criterion Observed value Value under estimated regime (95% C.I.)
Average utility 1.66 1.81 (1.72, 1.88)
Discounted utility 14.40 33.76 (19.24, 46.95)
Table 6: Comparison of the value under the observed regime and the value under the
estimated regime for average utility and discounted utility (γ = 0.95).
Figure 2: Estimated optimal treatment regime obtained by maximizing average utility,
which is projected onto a decision tree for interpretation. Each tree node shows the splitting
criterion, majority treatment label, and its proportion.
8 Conclusions
We developed a framework for estimation of an optimal treatment regime using data from
long-term observational or randomized clinical studies. From a precision medicine perspec-
tive, a key contribution of this work is incorporation of a patient’s latent health status,
e.g., their true mood state in the context of bipolar depression. We showed that using this
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structure can lead to estimated optimal regimes that are clinically meaningful and that
significantly outperform methods that fail to use this structure. From a methodological
perspective, a key contribution is the development of methods for estimation and inference
for the optimal treatment regime using from data generated from a POMDP. One could
generalize the proposed methodology to include continuous latent processes. Such an ap-
proach is aligned with existing work in POMDPs in the computer science and engineering
literature. We leave such extensions to future work.
Appendix I: Tables for medications
Medication name Low dose (mg) Medium dose (mg) High dose (mg)
Deseryl < 200 200− 400 > 400
Serzone < 200 200− 400 > 400
Citalopram < 20 20− 40 > 40
Escitalopram Oxalate < 10 10− 20 > 20
Prozac < 20 20− 40 > 40
Fluvoxamine < 100 100− 200 > 200
Paroxetine < 20 20− 40 > 40
Zoloft < 50 50− 100 > 100
Venlafaxine < 75 75− 150 > 150
Bupropion < 150 150− 300 > 300
Table 7: List of common antidepressants in STEP-BD. The dose is divided into 3 levels:
low, medium, and high.
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Medication name Low dose (mg) Medium dose (mg) High dose (mg)
Tegretol < 400 400− 800 > 800
Valproate < 1000 1000− 2000 > 2000
Olanzapine < 10 10− 20 > 20
Quetiapine < 400 400− 800 > 800
Clozapine < 200 200− 400 > 400
Lithium < 900 900− 1800 > 1800
Risperdal < 2 2− 4 > 4
Geodon < 80 80− 160 > 160
Abilify < 15 15− 30 > 30
Lamictal < 100 100− 200 > 200
Table 8: List of common mood stabilizers in STEP-BD. The dose is divided into 3 levels:
low, medium, and high.
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Appendix II: Estimated optimal treatment regime for
total discounted utility
Figure 3: Estimate optimal treatment regime by maximizing total discounted utility (γ =
0.95), which is projected onto a decision tree for interpretation. Each tree node shows the
splitting criterion, majority treatment label and its proportion.
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